Shareholder revolt at Meldex

Shareholders in specialty pharma group Meldex have called for assurances that the company will moderate its issuance of new equity to pay for acquisitions, and expressed concern about the depth of due diligence being performed on vendor companies. Their concerns are expected to take centre stage at the company's annual meeting today, ahead of which one of the company's non-executives has resigned.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now